Startup profile for Graph AI: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Graph AI funding, valuation and investors

AI-native pharmacovigilance platform (Graph Safety) that automates adverse-event intake and case processing for pharma and biotech.

Verified company research · funding, investors and latest developments

Keep track of Graph AI

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Series A

$13.3M · September 2026

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

$13M

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

series a · Pleasanton, California, USA

Investors in latest funding

Lead: Insight Partners

Other: Bessemer Venture Partners

Sources: latest funding · prnewswire.com Last verified: 2026-09-11

Overview

Graph AI builds Graph Safety, an AI-native patient-safety / pharmacovigilance platform with modules for adverse-event intake (/intake), case processing (/nucleus), and aggregate reporting (/report). Founded in 2024 and based in Pleasanton, California, it raised a $13.3 million Series A on September 10, 2026 led by Insight Partners with Bessemer Venture Partners participating after leading the October 2025 seed (company PR).

Why Graph AI is interesting

Insight-led $13.3M Series A on Sep 10, 2026 with Bessemer returning — company claims live deployments cut case turnaround from >3 hours to <10 minutes and operating costs up to 66%, turning services-heavy patient-safety ops into software.

Product & use cases

Regulated PV software: multi-channel AE capture, automated case processing with audit trails, and aggregate reporting — designed for FDA/EU AI expectations with human oversight.

  • Pharma / biotech safety ops replacing manual case workflows
  • Multi-channel adverse-event triage across intake channels
  • Inspection-ready case databases with traceable AI outputs

Key facts

  • $13.3M Series A led by Insight Partners; Bessemer participated (Sep 10, 2026)
  • Company: case TAT >3 hours → <10 minutes; opex down up to 66% in live deployments
  • Seed October 2025; /report module launching September 2026

Funding history (newest first)

Series A

2026-09 $13.3M
  • Insight Partners (lead)
  • Bessemer Venture Partners (participant)

Source: Read source · prnewswire.com

Seed

2025-10
  • Bessemer Venture Partners (lead)

Source: Read source · prnewswire.com

Market / IPO context

Editorial / static context — not a live quote.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.